Cohance Lifesciences Schedules Q4 & FY26 Results Conference Call for May 12
Cohance Lifesciences will host an investor and analyst conference call on May 12, 2026, at 6:30 PM IST. The call will discuss the company's audited financial results for Q4 & FY26, which will be declared earlier the same day. Pre-registration is available.
This is a standard procedural announcement for a financial results conference call and does not contain new material information that would significantly impact the company's stock price or operations.
The announcement is a routine schedule for a conference call to discuss financial results, with no new financial data or strategic changes presented.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced the schedule for a conference call with investors and analysts to discuss its audited financial results for the fourth quarter and full fiscal year 2026. The results are slated to be declared earlier on the same day.
The conference call is scheduled to take place on Tuesday, May 12, 2026, at 6:30 p.m. Indian Standard Time (IST). Senior management from Cohance Lifesciences will lead the call, commencing with a discussion of the Q4 & FY26 results, followed by an interactive Question & Answer session.
Participants can join the call using the provided dial-in numbers, including a primary number (+91 22 6280 1141 / +91 22 7115 8042) and international toll-free numbers for Singapore, Hong Kong, USA, and the UK. Pre-registration is encouraged via a provided link to receive dial-in details, passcode, and a PIN via email. Attendees are advised to dial in 5-10 minutes prior to the scheduled start time. Investor Relations contact details for Cohance Lifesciences and CDR India have also been shared for further information.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.